Key points from article :
Ochre plans to maintain hundreds of discarded donor livers outside the body, mimicking human physiological conditions, to test the efficacy of new RNA therapeutics.
The goal is improving liver transplant outcomes and discovering novel therapies for liver diseases.
Hoping to consistently perfuse organs for several days to study the effects of RNA therapy on liver performance.
Ochre announces partnerships with OrganOx, leaders in the field of liver perfusion technology, and Greg Tietjen’s lab at Yale University and LifeShare of Oklahoma.
These are donor livers that cannot be used for transplant patients for various reasons.
“We’re excited to announce this new research site in the US, as well as these partnerships with world leaders in liver perfusion research and transplant medicine,” said Jack O’Meara, Ochre Bio CEO.
"The unique capabilities of the OrganOx metra ... facilitating a new and exciting approach to developing novel therapeutics for liver diseases.” said Craig Marshall, OrganOx CEO
